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ANT1nuclear-encoded mitochondrial heart-muscle adenine nucleotide translocator-1
(ANT1), which exports mitochondrial ATP to the cytosol in both humans (ANT1−/−) and mice (Ant1−/−), results
in lactic acidosis and mitochondrial cardiomyopathy and myopathy, the latter involving hyper-proliferation of
mitochondria, induction of oxidative phosphorylation (OXPHOS) enzymes, increased reactive oxygen species
(ROS), and excessivemtDNAdamage. To understand thesemanifestations, we analyzed Ant1−/−mouse skeletal
muscle for changes in gene expression using our custom 644 and 1087 gene MITOCHIP microarrays and for
changes in the protein levels of key mitochondrial transcription factors. Thirty-four mRNAs were found to be
up-regulated and 29 mRNAs were down-regulated. Up-regulated mRNAs included the mitochondrial DNA
(mtDNA) polypeptide and rRNA genes, selected nuclear-encoded OXPHOS genes, and stress-response genes
including Mcl-1. Down-regulated mRNAs included glycolytic genes, pro-apoptotic genes, and c-Myc. The
mitochondrial regulatory proteins Pgc-1α, Nrf-1, Tfam, andmyogeninwere up-regulated and could account for
the induction of the OXPHOS and antioxidant enzymes. By contrast, c-Myc levels were reduced and might
account for a reduction in apoptotic potential. Therefore, the Ant1−/−mouse skeletal muscle demonstrates that
energy metabolism, antioxidant defenses, and apoptosis form an integrated metabolic network.
© 2008 Elsevier B.V. All rights reserved.1. IntroductionMitochondria play an important role in human health and disease as
they regulate cellular energy production, reactive oxygen species (ROS)
production, and apoptosis [1]. Mitochondria generate most of the cell's
energy by the process of OXPHOS. During OXPHOS, electrons are passed
down the electron transport chain (ETC), encompassing respiratory
complexes I–IV. As electrons traverse complexes I (NADH dehydrogen-
ase), III, and IV (cytochrome c oxidase), protons are pumped out across
the mitochondrial inner membrane creating an electrochemical
gradient. The resulting combination of membrane potential and pH
gradient, the proton motor force, is then used by the inner membrane
proton-transporting ATP synthase (complex V) as a source of potential
energy to drive the phosphorylation of ADP to ATP within the
mitochondrial matrix. Matrix ATP is then exported out of the mito-Mitochondrial Medicine and
om number 2014, Hewitt Hall,
+1 949 824 6388.
ll rights reserved.chondrion, in exchange for cytosolic ADP, by the adenine nucleotide
translocators (ANT).
Humans have four ANT isoforms that are encoded by four different
genes and are distributed in different tissue-speciﬁc patterns. The
human ANT1 gene is primarily expressed in the heart and in skeletal
muscle [2]. Human ANT2 is weakly expressed or absent from most
tissues, while human ANT3 is ubiquitously expressed [3]. The ANT1 and
ANT3 isoforms have been proposed to export ATP from the mitochon-
drialmatrix to the cytosol, while ANT2 has been proposed to be induced
whenmitochondrial energy production is impaired so that cytosolic ATP
can be imported into the mitochondrion to sustain mitochondrial
biogenesis and to maintain the membrane potential [4–6]. The fourth
humanANTgene,ANT4, is expressed at highest levels in the testes and at
lower levels in other organs including liver and brain [7]. Certain
missense mutations in ANT1 have been shown to cause autosomal
dominant progressive external ophthalmoplegia (AdPEO) [8,9], while
null mutations in ANT1 cause autosomal recessive mitochondrial myo-
pathy and cardiomyopathy [10].
Mice have three Ant isoforms encoded by three different genes.
Ant1 is expressed primarily in the heart and skeletal muscle, like its
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very low levels in skeletal muscle [11,12]. The murine equivalent to
human ANT4, Ant4, has a highly restricted expression pattern, with
mRNA only being detected in testes and germ cells [13,14].
Mice in which the Ant1 gene has been insertionally inactivated
develop an autosomal recessive (Ant1−/−) mitochondrial myopathy
and cardiomyopathy [11] that is essentially identical to that observed
in humans inheriting a homozygous null ANT1 mutation [10].
Systemic Ant1-deﬁcient mice (Ant1−/−) exercise intolerant in associa-
tion with ragged red muscle ﬁbers, massive proliferation of abnormal
mitochondria, and marked elevation in muscle OXPHOS enzyme
histochemistry. These mice also manifest metabolic abnormalities
including elevated resting serum, lactic acid and alanine and develop a
progressive hypertropic cardiomyopathy [11]. The Ant1−/− mouse
muscle and heart mitochondria also produce elevated levels of H2O2,
exhibit evidence of chronic oxidative stress, and have increased
numbers of mitochondrial DNA (mtDNA) rearrangements [15].
In addition to being the ATP/ADP translocase, the ANTs may be
important regulators of the mitochondrial permeability transition
pore (mtPTP) which in turn regulates apoptosis [16,17]. While
inactivation of the Ant1 and Ant2 genes in mouse liver markedly
decreased mtPTP calcium activation and rendered the mtPTP
insensitive to modulation by adenine nucleotide levels or atractylo-
side, loss of Ant1 and Ant2 did not eliminate the ability of the liver
mitochondria to undergo permeability transition [18]. Proteomic
analysis of the mouse liver mitochondrial inner membrane revealed
peptides for Ant2, Ant1, and a third Ant, presumably Ant4, in the ratio
of approximately 6:3:1 [19]. However, western blot analysis did not
detect Ant4 mRNA in liver [13]. Therefore, Ant1 and/or Ant2
predominate in liver mitochondria and are important in regulating
the liver mtPTP. Since over-expression of the human ANT1 or ANT3,
but not ANT2, genes has been shown to induce apoptosis in cultured
human cells [20,21], we can conclude that Ant1 (ANT1) regulates the
mtPTP and thus apoptosis in both human and mouse.
The hyper-proliferation of the mitochondria in the skeletal muscle of
the Ant1−/− mice has been correlated with an up-regulation of OXPHOS
gene expression by differential display reverse transcriptase-polymerase
chain reaction (RT-PCR) analysis. This method identiﬁed 17 over-ex-
pressedgenes in themutant tissueAnt1−/− animals including components
of the ETC as well as the muscle anti-apoptotic geneMcl-1 [22].
To obtain a more detailed picture of the effect of Ant1 deﬁciency on
muscle physiology,we compared the gene expressionproﬁles inAnt1−/−
skeletal muscle with those in wild-type muscle using our custom cDNA
microarrays. These MITOCHIPs contain either 644 or 1087 genes
relevant to energymetabolism,mitochondrial function, oxidative stress,
and apoptosis. We found that in Ant1−/− skeletal muscle 34 genes were
up-regulated including a number of OXPHOS geneswhile 29 geneswere
down-regulated including genes for glycolysis. This was associatedwith
an increase in the protein levels of a number of transcriptions factors
associated with induction of muscle oxidative metabolism including
peroxisome proliferator-activated receptor γ (PPARγ)-coactivator-1α
(PGC-1α, human; Pgc-1α, mouse), nuclear regulatory factor-1 (Nrf-1),
mitochondrial transcription factor A (Tfam), and myogenin. The cellular
Myelocytomatosis proto-oncogene gene and protein (c-Myc) was down-
regulated, which may have reduced the potential for induction of
apoptosis. These results imply that Ant1−/− mouse skeletal muscle
experiences energy starvation, oxidative stress, and apoptotic risk, and
attempts to compensate through induction of OXPHOS and antioxidant
defenses and the down-regulation of apoptosis.
2. Materials and methods
2.1. Assembly of MITOCHIP arrays
A majority of the genes represented on the MITOCHIP arrays were selected and
obtained from the NIA 15K mouse cDNA clone set [23]. The complete gene lists for
MITOCHIP v3 and v4 are provided in Supplemental Table I. In addition, the arrays alsocontained the differential display products isolated by Murdock et al. [22] as well as all
13 protein-coding mtDNA genes and the 2 rRNA mtDNA genes that were ampliﬁed in-
house. Other than the mtDNA genes, all the remaining cDNAs were ampliﬁed using the
primers and PCR regimen described in NIA15K [23]. After ampliﬁcation, the PCR
products were puriﬁed using 96-well Qiagen PCR puriﬁcation kits, and the dsDNA
concentration was determined by ﬂuorometry using the PicoGreen reagent (Invitro-
gen). The eluted pure PCR products were dried and reconstituted in 50% DMSO to a ﬁnal
DNA concentration of 75–100 ng/μl, and were then used for printing arrays. Arrays were
printed using a GMS-412 arrayer, on poly-L-lysine coated glass slides. Poly-L-lysine
coating, treatment and post-processing of slides were performed essentially as
described by DeRisi et al. [24], except that the succinic anhydride blocking step was
omitted. The slides were prehybridized in a solution of 25% formamide, 5X SSC, 0.1% SDS
and 1% BSA at 45 °C for 45–60 min just before use, rinsed in water, dried by
centrifugation at 500 rpm for 5 min and then used for hybridization.
2.2. Preparation of RNA
Total RNA was isolated from gastrocnemius muscles of wild-type and mutant
animals using Trizol reagent (Invitrogen) in accordance with the manufacturer's
protocol. The total RNA thus isolated was then treated with RNase-free DNase I (Roche)
for 30′ at room temperature to rid the sample of any contaminating DNA. After DNase I
treatment, the RNA was puriﬁed using RNeasy kits (Qiagen), quantitated by spectro-
photometry and used for labeling.
2.3. Hybridization of MITOCHIP arrays
25–30 μg of total RNA was labeled with either Cy3-dCTP or Cy5-dCTP by reverse
transcription for 2 h at 42 °C, in a mix containing 1X Superscript II Buffer (Invitrogen),
10mMDTT, 3 μgOligo-dT, 200 μMeach of dATP, dGTP and dTTP,100 μMdCTP and 100 μM
Cy3-dCTP or Cy5-dCTP (Amersham) and 400 units Superscript II (Invitrogen), with the
ﬁnal reaction volume being 35 μl. After reverse transcription the labeled cDNAwas rid of
RNAdenaturationwith 17.5 μl of 1.0 NNaOHat 70 °C for 10′, neutralizedwith 17.5 μl 1.0 N
HCl, and puriﬁed using PCR puriﬁcation columns (Qiagen). Equal amounts (picomoles of
incorporated labeled nucleotide) of wild-type and mutant labeled cDNA were mixed,
dried under vacuum, resuspended in 22 μl of hybridization buffer containing 25%
formamide, 5X SSC, 0.1% SDS, 1 μg polyA RNA (Sigma) and 1 μg mouse Cot1 DNA
(Invitrogen) and applied to the arrays. The arrays were incubated for 12–15 h at 55 °C,
and then washed three times at 55 °C with 2X SSC+0.1% SDS, three times with 1X SSC
+0.1% SDS at room temperature, and three timeswith 0.1X SSC at room temperature. The
incubations and washes were carried out in a GeneMachines HybStation (Genomic
Solutions). After the ﬁnal wash the slides were dried by rinsing with isopropanol
followed by centrifugation at 500 rpm for 5 min and scanned immediately.
2.4. Scanning and processing of data
The arrays were scanned in an Affymetrix scanner and quantitated using the
Imagene 4.1 software suite (BioDiscovery). The data was then exported into the
GeneSight Lite module (BioDiscovery) and normalized such that the sum of all ratios
was equal to one. The normalized data were then exported into Microsoft Excel where
the lists were sorted to exclude spots that were ﬂagged and were below background
intensity in each channel. All GeneSight ratios were converted to Log2 to provide a
symmetrical distribution around one for positive and negative values and average + or −
changes of greater than 1.5 obtained for both versions of the MITOCHIP or 1.7 for one
version of the MITOCHIP were reported.
2.5. Western blots
Total protein was isolated from gastrocnemius muscles of 9–12 month old wild-type
and Ant1−/− mice. One gastrocnemius muscle was homogenized in 2 ml of a buffer
containing 50 mM Tris pH 7.2, 100 mg/ml Sucrose, 0.1% SDS and 1 tablet/50 ml Complete
Protease Inhibitor cocktail (Roche). Thehomogenatewas spunat 1000 g for 10min and the
supernatant was carefully aspirated. Protein concentrations were determined using
Bradford's reagent. 40 μg of each protein sample was denatured in 1X (ﬁnal conc) NuPage
sample loading buffer (Invitrogen), run on10%or 12%NuPagegels (Invitrogen), transferred
to nitrocellulosemembranes, stainedwith PonceauS to ensure uniform loading and rinsed
in1Xwashbuffer (KPL). The blotswere thenblockedwith5%milk in1Xwashbuffer for 1h,
and incubated with primary antibody in 2% milk at 8–10 °C overnight. The primary
antibodywas washed off with 5–8 washes over 30minwith 1Xwash buffer, and the blots
were incubated for 2h in1Xwashbuffer containing the respective secondaryantibody. The
blots werewashed 5–8 times over 30min in 1Xwash buffer, and developed using the ECL
kit (Amersham) according to the manufacturer's protocols.
2.6. Antibodies and concentrations
Horse radish peroxidase (HRP)-conjugated secondary antibodies goat anti-mouse
(GAM), goat anti-rabbit (GAR) and rabbit anti-goat (RAG)were obtained from Santa Cruz
Biotechnology. Primary antibodies and concentrations used to detect the various
proteins were as follows: PGC-1α detected using PGC-1(P-19) or PGC-1(K-15) primary
antibody (Santa Cruz Biotechnology sc-5815 and sc-5816 respectively) at 1:500 dilution,
with RAG secondary at 1:5000; Nrf-1 detected using anti-NRF-1 serum (kindly provided
Table 1
Genes over-expressed in Ant1−/− skeletal muscle
Gene Set 1 Set 2
mtDNA OXPHOS subunits
mtDNA-ATPase 6 2.2 2.9
mtDNA-ATPase 8 3.3 3.1
mtDNA-COX 2⁎ 1.5 1.6
mtDNA-COX 3⁎ 2.9 2.9
mtDNA-Cyt b 3.1 3.9
mtDNA-NADH 1⁎ 1.8 2.6
mtDNA-NADH 2⁎ 2.6 2.3
mtDNA-NADH 3 2.5 1.6
mtDNA-NADH 4⁎ 2.4 2.2
mtDNA-NADH 4L⁎ 2.1 3.3
mtDNA-NADH 5⁎ 1.9 2.9
mtDNA-NADH 6⁎ 2.2 3.0
DD69 (mtDNA_ND5)⁎ 2.2 1.7
Nuclear OXPHOS subunits
NADH dehydrogenase (ubiquinone) Fe–S protein 4, 18 kDa
(NADH-coenzyme Q reductase) (Ndufs4)⁎
1.9 1.9
NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 5 (16 kD)
(Ndufb5)
1.6 1.7
NADH dehydrogenase (ubiquinone) 1, subcomplex unknown, 2
(14.5 kD) (Ndufc2)
1.6 1.5
Cytochrome c oxidase, subunit VIIa 2 (Cox7a2) 1.5 1.8
Other mitochondrial components
Solute carrier family 40 (iron-regulated transporter), member 1
(Slc40a1)
2.1 1.5
Translocase of inner mitochondrial membrane 8 homolog b (Timm8b) 1.6 1.7
Mitochondrial import inner membrane translocase subunit TIM8 A
(Deafness Dystonia Protein Homolog)
NP 1.6
mtDNA-12s rRNA 3.6 3.5
mtDNA-16s rRNA 2.5 2.5
Mitochondrial ribosomal protein L48 (Mrpl48)⁎ 2.7 1.7
Inner membrane protein, mitochondrial (Immt, mitoﬁlin) 2.4 1.6
Malate dehydrogenase, mitochondrial 1.8 1.6
Gene products enriched in oxidative muscle ﬁbers
Skeletal muscle LIM protein (Fhl1) 1.8 1.6
ATPase, Ca++ transporting, cardiac muscle, slow-twitch 2 (Atp2a2) 1.5 1.5
Mus musculus ATPase, Na+/K+ transporting, beta 1 polypeptide
(Atp1b1)
1.5 1.6
Mus musculus malate dehydrogenase, soluble (Mor2)⁎ 1.5 1.9
Stress response
Microsomal glutathione S-transferase 1 (Mgst1) 1.6 1.5
Antigenic determinant of RecA protein (Kin 17)⁎ NP 2.8
Myeloid cell leukemia sequence 1 (Mcl1)⁎ 1.5 1.5
Miscellaneous
Nrbf1 NP 2.7
Ornithine decarboxylase antizyme 3 (Oaz3) 1.7 2.7
Homolog of Unc33/collapsin response mediated protein 2 (Crmp2) 3.1 3.5
⁎ = Also identiﬁed as up-regulated by Murdock et al. [22].
NP = Not present in that version of the MITOCHIP.
668 V. Subramaniam et al. / Biochimica et Biophysica Acta 1777 (2008) 666–675by Dr. R.C.Scarpulla) at 1:5000 dilution with GAR secondary at 1:5000; Tfam detected
using anti-Tfam polyclonal serum (kindly provided by Dr. Gerald Shadel) at 1:10,000
with GAR secondary at 1:5000; mt-COI detected using monoclonal antibody 1D6
(Molecular Probes) at 100 ng/ml with GAM secondary at 1:10,000; myogenin detected
using M-225 primary antibody (Santa Cruz Biotechnology sc-576) at 1:500 with GAR
secondary at 1:5000; Myoglobin detected using M-19 primary antibody (Santa Cruz
Biotechnology sc-8081) at 1:500 with RAG secondary at 1:5000; TnI-slow detected
using TnI SS C-19 primary (Santa Cruz Biotechnology sc-8119) at 1:1000 with RAG
secondary at 1:5000; TnI-fast detected using TnI FS C-19 primary (Santa Cruz
Biotechnology sc-8120) at 1:1000 and RAG secondary at 1:5000; Myc was detected
using monoclonal anti-c-myc 9E10 (Sigma M5546) at 1:5000 with GAM secondary at
1:5000.
3. Results
Gene expression differences between skeletal muscles from Ant1−/−
and wild-type mice were studied using two versions of our mouse
MITOCHIP, MITOCHIP vM3 containing 772 elements (representing 644
genes) and MITOCHIP vM4 containing 1152 elements (representing
1089 genes). Four experimentswere performedwith each version of the
MITOCHIP. In each experiment, a pool of skeletal muscle RNA from at
least 3Ant1−/−micewas compared to a pool of skeletalmuscle RNA from
at least 3wild-typemice. In all, tissues from11 differentmutant animals
were compared with tissues from 11 different age-matched wild-type
animals over the 8 experiments.
The differential fold-expression values for each gene from the four
experiments using MITOCHIPv3 (Set 1) were averaged, as were those
for the four experiments using MITOCHIP v4 (Set 2). Genes showing
average expression differences of at least 1.5-fold in both Set 1 and Set
2 were considered to be signiﬁcant. In instances where the gene was
not represented in Set 1, an average differential expression of at least
1.7-fold in the Set 2 experiments was considered signiﬁcant.
3.1. Genes up-regulated in Ant1−/− skeletal muscle
In all, 34 differentmRNAswere found to be over-expressed inAnt1−/−
skeletal muscle relative to wild type (Table 1). These genes can be
classiﬁed broadly into the following functional categories: (i) genes
encoding components of the mitochondrial OXPHOS machinery; (ii)
genes for other mitochondrial components; (iii) genes whose products
are enriched in slow-twitch (oxidative) muscle ﬁbers; (iv) genes for
stress response, and (v)miscellaneous genes. As canbe seen fromTable 1,
a number of the genes identiﬁed as up-regulated using the MITOCHIPs
were also previously shown to be up-regulated by differential and
northern analysis of mRNA from Ant1−/− skeletal muscle (18).
3.1.1. OXPHOS components
Sixteen of the 34 up-regulated genes encode subunits of the
mitochondrial OXPHOS. Twelve of the 13 mRNAs encoded by the
mtDNA were found to be strongly up-regulated in Ant1−/− muscle. Of
the nuclear OXPHOS subunit mRNAs that are up-regulated, 3 belonged
to complex I (Ndufs4, Ndufb5 and Ndufc2) while one belonged to
complex IV (Cox7a2). Interestingly, Ndufs4 has been shown to be
essential for the assembly of Complex I in humans [25], while Cox7a2
has been shown to be essential for assembly of Complex IV inyeast [26]
and Dictyostelium [27]. The induction of mtDNA and nDNA OXPHOS
proteins is consistent with the hyper-proliferation of mitochondrial
and the increased complex II and IV staining in the Ant1−/− skeletal
muscle [11,15,22].
One transcript encodedby themtDNA, cytochrome c oxidase I (mt-CO1),
yieldedverypoor signal onourarrays, though the reason for this isunclear.
Since the mitochondrial DNA H-strand is transcribed as a polycistronic
unit [28], it is unlikely that transcriptional differences can account for this
discrepancy. However, certain mtDNA transcripts can have short half lifes
[29] and thus the mt-CO1 mRNAs may have a differential stability rela-
tive to othermtDNA-encodedmRNAs. Indeed a previous study found that
mt-CO1 mRNA levels were disproportionately regulated relative to other
mtDNA and nDNA complex IV subunits in neurons [30].To clarify themt-CO1mRNA levels,weusedReal-TimePCRand found
that themt-COImRNAwas increased approximately 1.6-fold in Ant1−/−
skeletal muscle (not shown). The levels of COI protein were also
increased in Ant1−/− skeletal muscle (Fig. 1D). Hence, all of the mtDNA-
encoded OXPHOS genes were up-regulated in the Ant1−/−muscle.
3.1.2. Other mitochondrial components
mRNAs for three mitochondrial transporters were also up-
regulated in Ant1−/− skeletal muscle. Slc40a1 (also called ferroportin)
encodes a regulated iron transporter that appears to function mainly
in the export of iron. Ferroportin over-expression has been shown to
cause iron depletion in cultured cells [31] andmutations in ferroportin
have been shown to cause diseases of iron overload in humans [32].
Timm8a and Timm8b encode components of the mitochondrial
protein import machinery, essential for mitochondrial biogenesis.
Mutations in Timm8a have been shown to cause deafness–dystonia–
optic atrophy (Mohr-Tranebjaerg) syndrome in humans [33].
Fig. 1. Proteins that regulate mitochondrial proliferation are over-expressed in Ant 1−/− skeletal muscle. Western blots showing levels in Ant1+/+ and Ant1−/− skeletal muscle of the
following proteins: (a) Pgc-1α detected using antibody P-19 (amino terminus-speciﬁc) and K-15 (carboxy terminus-speciﬁc), (b) Nrf-1, (c) Tfam, (d) mtCO1, (e) Myogenin, (f) Myc
(two different blots, both probed with antibody 9E10, (g) Tnni1, (h) Tnni2, and (i) Myoglobin.
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Ant1−/− skeletal muscle: three components of the mitochondrial
ribosome [mtDNA 12S-rRNA (mt-rnr1), mtDNA 16S-rRNA (mt-rnr2)
and mitochondrial ribosomal protein L52 (Mrpl48)], the TCA cycle
enzyme malate dehydrogenase (Mor2), and mitoﬁlin. Mitoﬁlin is a
mitochondrial inner membrane protein important in cristae structure,
whose reduction leads to the collapse of the cristae network, in-
creased membrane potential, and ROS production [34]. Mitoﬁlin is
also induced in brown adipose tissue when exposed to cold [35].
3.1.3. Oxidative muscle-ﬁber-speciﬁc genes
The strong up-regulation of mitochondrial transcripts in Ant1−/−
skeletal muscle indicates that the mutant muscle is attempting to
compensate for the energy starvation by inducing OXPHOS. This
notion is supported by the fact that the products of several over-
expressed genes have also been shown to be enriched in slow-twitch
or oxidative (Type I) muscle ﬁbers. The skeletal muscle LIM domain
protein (Fhl1), and cytoplasmic malate dehydrogenase (Mor2) have
been shown to be over-expressed in soleus (an almost exclusively
oxidative, slow-twitch, muscle type) relative to the white quadriceps
muscle (an almost exclusively glycolytic, fast-twitch, muscle type)
[36]. Further, the Ca++ transporting ATPase subunit (Atp2a2) as well as
the Na+/K+ transporting ATPase subunit (ATP1b1) has been shown to
be enriched in oxidative, slow-twitch, muscle ﬁbers [37–39] relative to
glycolytic, fast-twitch, muscle ﬁbers.
3.1.4. Stress-response genes
mRNAs encoding three different stress-response proteins were
found to be over-expressed in Ant1−/− skeletal muscle. Of these,
microsomal glutathione S-transferase mu (Mgst1) is a membrane
bound protein that has been shown to have glutathione transferase
and glutathione peroxidase activities [40], and to protect cells from
oxidative stress [41,42]. The other two stress-response genes up-
regulated in Ant1−/− skeletal muscle are Kin 17 and Mcl-1. The Kin 17
protein is induced in response to UV and ionizing radiation [43,44]
and has been shown to bind to curved DNA spanning stretches ofillegitimate recombination [45]. Mcl-1 is an anti-apoptotic protein of
the Bcl-2 family [46] and protects cells from apoptosis under a variety
of conditions [47]. Mcl-1 has also been shown to be induced in
response to oxidative stress [48].
3.1.5. Miscellaneous
The three remaining genes that are up-regulated in Ant1−/− skeletal
muscle (Nrbf1, Oaz3 and Crmp2) do not ﬁt into any speciﬁc functional
category but are interesting nevertheless. Nrbf1 was identiﬁed in a two-
hybrid screen as a PPAR-α interacting protein. Nrbf1 was also shown to
be able to interact with a variety of nuclear hormone receptors such as
thyroid hormone receptor β (TRβ), retinoid acid receptor α (RARα),
retinoid X receptor α (RXRα), and hepatocyte nuclear factor 4 (HNF4).
Nrbf1 shares homology with the yeast protein MRF-1, a putative tran-
scription factor regulating the expression of mitochondrial respiratory
proteins [49]. Crmp2 (Collapsinmediated response protein 2) belongs to
a family of molecules that are involved in axonal growth cone guidance
[50], while Oaz3 encodes an ornithine decarboxylase antizyme [51].
3.2. Genes down-regulated in Ant1−/− skeletal muscle
In all, mRNAs from 29 different genes were found to be down-
regulated in Ant1−/− skeletal muscle relative to wild type (Table 2).
These genes encompass a variety of functions including metabolic
enzymes, pro-apoptotic genes, signaling molecules, transporters, and
others. Two classes of these genes (metabolic enzymes and apoptotic
genes) are particularly interesting in the context of this study and will
be discussed in more detail below.
3.2.1. Metabolic enzymes
Six metabolic enzyme genes were down-regulated in Ant1−/−
skeletal muscle relative to wild type (Table 2). Two of these are key
glycolytic enzymes and thus genes, 6-phosphofructo 2-kinase (Pfkfb3)
and Aldolase B (Aldob). Like mitochondrial proliferation, the down-
regulation of these glycolytic genes may be indicative of the shift of
the skeletal muscle in Ant1−/− animals to a more oxidative physiology.
Table 2
Genes under-expressed in Ant1−/− skeletal muscle
Gene Set 1 Set 2
Metabolic enzymes
Inducible 6-phosphofructo-2-kinase (Pfkfb3) NP −3.0
Aldolase B −8.2 −2.7
Protoporphyrinogen oxidase (Ppox) −2.0 −1.5
Cytochrome P450 side chain cleavage enzyme 11a1 (Cyp11a1) NP −1.9
Ornithine decarboxylase antizyme 2 (Oaz2) −1.6 −1.6
Apoptosis effectors
Modulator of apoptosis (Moap1) NP −1.8
Bcl2-interacting killer-like (Biklk), mRNA NP −1.8
Myelocytomatosis oncogene (Myc) NP −1.9
RAD53 homolog (Chek2) NP −1.8
Phospholipase A2, group VI (Pla2g6) NP −2.4
Myc target genes
N-myc downstream regulated 1 (Ndr1) NP −2.2
Ornithine decarboxylase, structural (Odc) −3.2 −2.3
Transporters
Bumetanide-sensitive sodium–(potassium)-chloride cotransporter 1
(Slc12a2)
−1.6 −1.5
Solute carrier family 30 (zinc transporter), member 3 (Slc30a3) −1.6 −1.6
Adenine nucleotide translocase-2 (Ant2) −3.4 −3.4
Kinases
LIM motif-containing protein kinase 2 (Limk2) NP −1.7
Casein kinase I alpha isoform (CSNK1A1) NP −1.9
Casein kinase 1, epsilon (Csnk1e) NP −1.9
Homeodomain interacting protein kinase 3 (Hipk3) −2.0 −1.7
Mitogen-activated protein kinase kinase kinase 12 (Map3k12) NP −1.9
Rho-associated coiled-coil forming kinase 1 (Rock1) NP −1.7
Signaling
Protein tyrosine phosphatase, non-receptor type 21 (Ptpn21) NP −2.0
Mothers against Dpp homolog 1 (Madh1) NP −1.7
Signal transducer and activator of transcription interacting protein 1
(Statip1)
NP −1.7
Activin receptor IIB (Acvr2b) NP −1.7
Heat shock proteins
Crystallin, alpha C (Hsp 20) NP −1.8
Heat shock protein, 86 kDa 1 (Hsp86-1) NP −1.7
Other
Ubiquinol-cytochrome c reductase core protein 1 (Uqcrc1) −1.6 −1.6
Microtubule-associated protein 4 (Mtap4) NP −1.9
NP = Not present on that version of the MITOCHIP.
Table 3
Expression of glucose metabolism genes in Ant1−/− skeletal muscle
Gene Mean fold expression
Glycolysis and pyruvate metabolism
Mus musculus phosphofructokinase, muscle (Pfkm) −1.1
Mus musculus inducible 6-phosphofructo-2-kinase (Pfkfb3) −2.9
Mus musculus aldolase 1, A isoform (Aldoa) −1.6
Aldolase B (Aldob) −3.4
Mus musculus triosephosphate isomerase (Tpi1) −1.5
GAPDH −1.3
Mus musculus phosphoglycerate mutase 1 (Pgam1) 1.0
3-Phosphoglycerate dehydrogenase −1.3
Mus musculus enolase 1, alpha non-neuron (Eno1) −1.4
Mus musculus pyruvate kinase 3 (Pk3) −1.3
Mus musculus lactate dehydrogenase 1, A chain (Ldh1) −1.5
Alanine aminotransferase 1.2
Alanine aminotransferase 2 (muscle speciﬁc) −1.4
Pentose phosphate pathway
Mus musculus glucose-6-phosphate dehydrogenase X-linked
(G6pdx)
1.5
Tricarboxylic acid cycle
Isocitrate dehydrogenase 2 (NADP+), mitochondrial (Idh2) 1.2
Isocitrate dehydrogenase 3 (NAD+) alpha (Idh3a) 1.2
Aconitase 2, mitochondrial (Aco2) 1.1
ATP-speciﬁc succinyl-CoA synthetase beta subunit 1.2
Succinate dehydrogenase (ubiquinone) Flavoprotein subunit,
mitochondrial
1.4
SDHD gene_small subunit of cytochrome b of succinate
dehydrogenase
1.5
Fumarate hydratase (FH) 1.4
Malate dehydrogenase, mitochondrial (DD67) 1.6
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levels of all the genes involved in glucose metabolism across our eight
MITOCHIP experiments (Table 3).
As can be seen from Table 3, genes encoding glycolytic enzymes
appear generally down-regulated in Ant1−/− skeletal muscle. In
addition to Pfkfb3 and AldoB mentioned above, the genes for Aldolase
I (Aldoa), Triosephosphate isomerase (Tpi1) and Enolase I (EnoI) were
all down-regulated at least 1.4-fold. Also, Ldh1 (encoding lactate
dehydrogenase A chain which converts pyruvate to lactate) and Aat2
(muscle-speciﬁc alanine aminotransferase which converts pyruvate to
alanine) were down-regulated by 1.5 and 1.4-fold, respectively.
The MITOCHIP results also suggest that the Ant2 gene may have
been down-regulated, though the very low expression of this gene in
skeletal muscle [11,12] renders any estimate of extent of change
immaterial. What is clear is that Ant2 was NOT up-regulated in the
Ant1−/− muscle. This has been conﬁrmed for both Ant2 mRNA in
Northern blots and Ant2 protein in western blots (see Figs. 3c and d,
respectively in [11]). The absence of induction of the Ant2 gene in the
face of Ant1 deﬁciency initially seemed counter-institutive, since the
simplest way to resolve the Ant1 deﬁciency would seem to have been
induction of another Ant isoform that would complement the defect.
Since the Ant2 gene is the only other systemic mouse Ant isoform,induction of this genewould have been the logical choice. One possible
explanation for this anomaly could be that themouse Ant2 protein has
a similar function and properties as the human ANT2 protein. In
contrast to ANT1 and ANT3, human ANT2 has been proposed to import
cytosolic ATP into the mitochondria during periods of mitochondrial
dysfunction, for example in hypoxia [5,6]. If this is true for the mouse
Ant2, then up-regulation of the Ant2 protein would not complement
the Ant1 deﬁciency, but rather make the sarcoplasmic ATP deﬁciency
worse. This would also explain the very low expression of Ant2 in
skeletal muscle, where ATP would consistently need to be transported
out of the mitochondrion to support muscle contraction and plasma
membrane transport. Similarly, if Ant2 functions to import ATP into the
mitochondria during hypoxia, then the gene should be induced during
hypoxia, not hyperoxia as would be the situation in Ant1−/− skeletal
muscle. Therefore, the lack of induction ofAnt2may reﬂect its converse
function, relative to Ant1, rendering it both biochemically unable to
complement Ant1 deﬁciency and inappropriately regulated to do so.
Table 3 also shows thatmRNAs for several enzymes of the TCA cycle
are moderately up-regulated in Ant1−/− skeletal muscle. This is
consistent with the mitochondrial proliferation and associated induc-
tion of mitochondrial energy production in an effort to compensate for
the cytosolic ATP deﬁciency.
Interestingly, G6pdx [glucose-6-phosphate dehydrogenase, which
catalyzes the ﬁrst and rate-limiting step of the Pentose Phosphate
Pathway (PPP)] is over-expressed 1.5-fold in Ant1−/− skeletal muscle.
The PPP providesmuch of the reducing power in the cell in the form of
NADPH, and NADPH is important formaintaining reduced glutathione.
Since ﬂux through the PPP and the rates of NADPH production are
directly proportional to glucose-6-phosphate dehydrogenase activity;
then increased G6pdx expression may be is indicative of an increased
demand for NADPH to manage oxidative stress.
The three remaining down-regulated genes were Ppox, Cyp11a1,
and Odc1. The Ppox gene encodes the enzyme protoporphyrinogen
oxidase, which catalyzes the penultimate reaction in heme biosynth-
esis. Mutations in the Ppox gene have been shown to cause variegated
porphyria in humans [52]. The Cyp11a1 gene encodes the cytochrome
671V. Subramaniam et al. / Biochimica et Biophysica Acta 1777 (2008) 666–675P450 side chain cleaving enzyme that catalyzes the ﬁrst step of
cholesterol biosynthesis [53]. The Odc1 gene encodes ornithine
decarboxylase, the key enzyme in the biosynthesis of polyamines
which play central roles in cell proliferation and survival [54]. Down-
regulation of Odc1 should cause the down-regulation of polyamine
biosynthesis in Ant1−/− skeletal muscle.
3.2.2. Genes that regulate apoptosis
Several genes that encode pro-apoptotic genes were also down-
regulated in Ant1−/− skeletal muscle including Myc, Modulator of
apoptosis (Moap1), Bcl2-interacting killer (Bik), Chk2 checkpoint
homolog (Chek2), and Phospholipase A2, group VI (Pla2g6). This
suggests that the apoptotic threshold may be higher in the Ant1−/−
skeletal muscle. The Myc oncogene regulates two complex and
seemingly contradictory sets of regulatory pathways. While Myc
over-expression or activation has been shown to be a key event in
many cancers, Myc over-expression can also activate apoptotic
pathways in a normal cell under conditions of serum deprivation or
DNA damage [55]. Myc has been shown to promote cell death by
suppressing the activity of the Cdk-inhibitor p21/Cip1 [56] and thus
shifting the choice of cellular DNA-damage response from cytostatic to
apoptotic. The down-regulation ofMyc in Ant1−/− skeletal muscle was
also conﬁrmed at the protein level by western blotting (Fig. 1F).
TheMoap1 gene was identiﬁed in a two-hybrid screen as encoding
a protein that interacts with the apoptosis effector Bax. Moap1 has
been shown to cause caspase-dependent apoptosis when over-
expressed in cell culture [57,58].
The Bik gene also encodes a potent death agonist. Over-expression
of Bik causes caspase-dependent apoptosis in cell culture, and its
apoptotic activity can be suppressed by co-over-expression of Bcl-2 or
Bcl-XL [59]. The mouse Chek2, is required for p53 mediated DNA-
damage response. Analyses of Chek2−/− mice have revealed that
Chek2 is required for p53 mediated apoptosis in response to ionizing
radiation. Thus, Chek2, likeMyc, also appears to be involved in shifting
the choice of the p53 pathway from cytostatic to apoptotic [60].
Finally, Pla2g6 has been shown to mediate Fas-induced cell death by
causing the release of arachidonic acid. Pla2g6 may also be involved in
regulating ion-channel activity and membrane phospholipids remo-
deling during apoptosis and inhibition of Pla2g6 has been shown to
decrease Fas-induced cell death [61].
3.2.3. (iii) Other genes under-expressed in Ant1−/− muscle
As can be seen from Table 2, several kinases, signaling molecules,
transporters and other genes are down-regulated in Ant1−/− skeletal
muscle. It is difﬁcult to classify these genes further from a standpoint of
metabolic pathways. However some of them do have common regu-
latory links. The genes for microtubule associated protein 4 (Mtap4) and
heat shock protein 90 (Hsp86-1) (as well as Odc1 and several glucose
metabolism genes) are known targets of Myc [62,63]. Thus their down-
regulation may be a consequence of the down-regulation of Myc in
Ant1−/− skeletal muscle. Also, some of the down-regulated mRNAs
may also be ones that are normally enriched in glycolytic muscle ﬁbers,
and their reduced expression may also be a result of the change in the
metabolic nature of the muscle ﬁbers in Ant1−/− animals.
3.3. Molecular basis of the mitochondrial proliferation in Ant1−/−
skeletal muscle
Mitochondrial proliferation and changes in muscle-ﬁber physiol-
ogy and composition can be triggered by endurance training and
exercise [64]. This process has been shown to be mediated by the
PPARγ associated transcriptional coactivator-1α (PGC-1α) [65,66].
PGC-1α has also been shown, in ectopic expression studies, to be a
master regulator of mitochondrial proliferation and muscle-ﬁber-type
switching [67] acting through regulation of transcription factors
required for mitochondrial proliferation such as Nrf-1 and Tfam [66].Since we see marked mitochondrial proliferation as well as over-
expression of several slow-twitch muscle-ﬁber markers in Ant1−/−
muscle, we examined whether these changes were also reﬂected the
PGC-1α transcriptionpathway. As can be seen in Fig.1A–C, the levels of
Pgc-1α, Nrf-1 and Tfam proteins were all elevated in Ant1−/− skeletal
muscle, indicating that the mitochondrial proliferation observed in
Ant1−/− skeletal muscle is mediated by the PGC-1α pathway.
Interestingly, the levels of Pgc-1α mRNA appear to be slightly lower
in Ant1−/− skeletalmuscle relative towild type, as assayed by real-time
PCR (not shown). However, Pgc-1α can be regulated by either
transcriptional and/or post-transcriptional mechanisms [68–75].
To investigate whether the observed changes in Ant1−/− skeletal
muscle were due to changes in ﬁber-type composition of the muscle
(from fast-twitch to slow-twitch), or simply due to the metabolic
nature of the muscle ﬁbers, we examined the levels of myoglobin,
Troponin I-slow (Tnni1; normally enriched in slow-twitch muscle
ﬁbers) and Troponin I-fast (Tnni2; normally enriched in fast-twitch
muscle ﬁbers) in Ant1−/− skeletal muscle. As can be seen in Fig. 1G–I,
the levels of Tnni1, Tnni2 andmyoglobin are not signiﬁcantly different
in Ant1−/− skeletal muscle compared to wild type. Immunohisto-
chemical staining for different myosin heavy chain (MHC) isoforms
also showed no signiﬁcant change in the levels or distribution of the
slow-twitch speciﬁc MHC isoforms in Ant1−/− skeletal muscle (A.Flierl
and DC Wallace, unpublished results). While elevated expression of
PGC-1α can induce a change inmuscle-ﬁber type, it neednot necessarily
do so. Indeed, over-expression of one of the targets of PGC-1, myogenin,
has been shown to promote increased oxidative metabolism in skeletal
muscle ﬁbers without effecting a complete change in muscle-ﬁber type
[76]. As can be seen in Fig. 1E, levels of myogenin are signiﬁcantly
elevated inAnt1−/− skeletalmuscle compared towild type. These results
are all consistentwith the idea that the skeletal muscle ﬁbers in Ant1−/−
animals adopt amore oxidativemetabolismwithout changing the ﬁber-
type composition of the muscle.
4. Discussion
The skeletal muscle of Ant1−/− mice presents a fascinating
regulatory conundrum from the standpoint of energy metabolism.
On the one hand, the complete deﬁciency of Ant1 blocks virtually all
transport of mitochondrial ATP into the cytosol, thus creating a severe
energy deﬁciency within the nuclear-cytosol compartment of the
muscle cells. As a result, there is little ATP for sarcoplasmic muscle
contraction, ion transport, biogenesis, etc. causing severe exercise
intolerance in the mice [11].
On the other hand, mitochondrial OXPHOS is fully functional and is
even strongly up-regulated, as evidenced by the hyper-proliferation of
skeletal muscle mitochondria and the strong induction of succinate
dehydrogenase (complex II) and complex IV. Hence, the intra-
mitochondrial ATP level would be expected to be near maximum.
Indeed, the high resting serum lactate and alanine levels are indicative
of a ‘stalled’ mitochondrial OXPHOS and TCA cycle. This would be the
result if the mitochondrial matrix adenine nucleotides were maxi-
mally phosphorylated, thus depriving the ATP synthase of its ADP
substrate. In the absence of ADP, the ﬂux of protons through the ATP
synthase proton channel would stop, and the mitochondrial mem-
brane potential would remain hyper-polarized, blocking further
proton pumping and stalling the ETC. Inhibition of the ETC, would
also stall the TCA cycle, resulting in the accumulation of cytosolic
pyruvate and NADH+H+, which would be converted to lactate and
alanine [11].
With the mitochondrial ETC stalled, in the present of unlimited
calories, the electron carriers would become fully reduced. Given a
hyperoxic state, the excess electrons could readily be transferred
directly to O2 to generate superoxide anion and the other ROS. The
chronically elevated ROS would then damage the mitochondria and
mtDNA in skeletal muscle and heart [15].
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molecular circuitry of energymetabolism,we employed theMITOCHIP
to analyze changes in the transcript levels of over 1000 genes that are
associated with energymetabolism, ROS biology, and apoptosis. These
mRNAanalyseswere complementedbyexamining the protein levels of
transcription factors known to regulate the expression of energy,
antioxidant, and apoptotic genes. Our results revealed that the Ant1−/−
skeletal muscle: (i) is starved for energy and is attempting to
compensate for this energy deﬁcit by inducing oxidative metabolism
while down-regulating glycolysis; (ii) is under oxidative stress and is
attempting to combat this stress by up-regulating antioxidant defenses;
(iii) is inducing oxidative metabolism and antioxidant defenses through
increased levels of nuclear (Pgc-1α, Nrf-1, and myogenin) and
mitochondrial (Tfam) DNA transcription factors; (iv) is at increased
risk for apoptosis and is compensating by up-regulating anti-apoptotic
and down-regulating pro-apoptotic genes; and (v) appears to be down-
regulating the apoptotic pathways by decreased c-Myc.
4.1. The metabolic reorganization of Ant1−/− mouse skeletal muscles
Previously, we had shown that as human myoblasts differentiate
intomyotubes, the expression ofmtDNA- and nDNA-encodedOXPHOS
genes and of nDNA-encoded glycolytic genes change expression
reciprocally. When myoblasts are differentiated in normoxic condi-
tions, OXPHOS genes are up-regulated in myoblasts, down-regulated
after commitment to differentiation, and up-regulated again in
myotubes. ANT1 is not expressed in myoblasts but is progressively
induced as myotubes are formed. By contrast, the glycolytic genes are
down-regulated in myoblasts, up-regulated after commitment, and
decline asmyotubes are formed. If themyoblasts aredifferentiated into
myotubes under hypoxic condition, however, the glycolytic gene
expression levels remain high in the myotubes. As a consequence, by
sevendays after commitment the glycolyticmRNAshave increased six-
fold relative to OXPHOS transcripts [77].
While the ETC is stalled in the Ant1−/− mouse skeletal muscle, the
cardiovascular system remains functional. Therefore, oxygen continues
to be delivered to the muscle but cannot be consumed by the mito-
chondriaOXPHOS. Hence, theAnt1−/−muscle should becomehyperoxic.
In the hyperoxic state Ant1−/− muscle is attempting to compensate for
the cytosolic ATP deﬁciency by up-regulating mitochondrial OXPHOS.
However, this is futile due to the absence of Ant1, resulting in
uncontrolled proliferation of the mitochondria [11]. All the mtDNA
OXPHOS genes as well as four nuclear-encoded OXPHOS genes are
signiﬁcantly up-regulated in the Ant1 deﬁcient muscle, with two of the
nuclear-encoded proteins, Ndufs4 and Cox7a2, being involved in the
assembly of complex I and complex IV, respectively [25–27]. The fact
thatmajor up-regulated nuclear OXPHOS genes are involved in complex
assembly suggests that most nuclear-encoded components of the ETC
are not normally limiting in muscle and that the number of functional
ETC complexes may be regulated at the level of complex assembly.
The up-regulation of several oxidative muscle-ﬁber-speciﬁc mar-
ker genes including Fhl1, Mor2, Atp2a2, and Atp1b1 is also consistent
the Ant1−/− muscle's attempting to compensate for the energy
deﬁciency by up-regulating oxidative metabolism. However, this is
not associated with ﬁber-type switching, since the myoglobin levels
and troponin I and myosin heavy chain isoforms did not change.
Hence, the primary response to the reduction in the sarcoplasmic ATP
appears to be the up-regulation of mitochondrial OXPHOS.
Assuming that mouse and human muscles are under similar
regulation, we would expect that the induction of mitochondrial
OXPHOS should be associated with the reciprocal down-regulation of
glycolysis, which we observed. Both the 6-phosphofructo-2-kinase
(Pfkfb3) and aldolase B genes were strongly down-regulated, in
parallel with the down-regulation of several other glycolytic genes
including the lactate dehydrogenase A (Ldh1) and muscle-speciﬁc
alanine aminotransferase (Aat2) genes. Therefore, the “standard”muscle response to low sarcoplasmic ATP in the presence of normoxia
is induction of OXPHOS and reduction of glycolysis.
The “standard” program for energy deﬁcient muscle under
normoxia proves to be exactly the wrong response when the cytosolic
ATP deﬁciency is caused by Ant1 deﬁciency. The only source of ATP for
the cytosol is then glycolysis. Since carbohydrates are not limiting, the
resulting ﬂux of carbohydrates through glycolysis is high. With
OXPHOS and the TCA cycle stalled, pyruvate and NADH+H+ accumu-
late and are combined by lactate dehydrogenase to generate lactate.
Since lactate is both the end product of glycolysis but also a substrate
for OXPHOS, it is unclear if the Ant1−/− muscle would strive to export
the excess lactate to control intra-cellular pH or import the lactate in a
further attempt to bolster mitochondrial ATP production. Insight into
this question might be obtained by analyzing the expression of the
proton-linked monocarboxylate transporter (MCT) isoforms. Isoform
MCT1 is expressed in Type I oxidative ﬁbers and is thought to import
lactate into muscle cells to be oxidized by OXPHOS, while isoform
MCT4 is present in all muscles but at lower levels in oxidative muscle
and is thought to export excess glycolytic lactate [78].
An alternative approach to increasing sarcoplasmic ATP would be
to induce an alternative adenine nucleotide translocator, thus
restoring the export of the excess mitochondrial ATP. Ant2 would be
the logical choice, since it is expressed in virtually every tissue.
However, Ant2 was NOT up-regulated [11]. This anomaly might be
explained if Ant2 functions like the human ANT2 to import cytosolic
ATP into themitochondrion under anoxic conditions [5,6]. If this is the
case, then Ant2 should be induced under anoxic conditions and
repressed under normoxic conditions, which is consistent with what
we observed in the Ant1−/− mouse muscle.
Given the high rate of ROS production by the Ant1−/−muscle [15], we
would expect the mitochondrial antioxidant defenses to be induced.
While the steady state mRNA levels for the mitochondrial antioxidant
genes were only mildly elevated, western blot analysis revealed that
mitochondrial manganese superoxide dismutase (MnSOD) is induced
six-fold and glutathione peroxidase-1 is induced three-fold in theAnt1−/−
muscle [15]. In addition, the MITOCHIP revealed that other stress-
response genes were up-regulated in Ant1−/− skeletal muscle: Mgst1,
G6pdx, and Kin17. Mgst1 is involved in protecting membranes and cells
from lipid peroxidation damage, consistent with high oxidative stress.
Glucose-6-phosphate dehydrogenase (G6pdx), the rate-limiting enzyme
in the pentose phosphate pathway (PPP) and the primary source of
NADPH, would be important in sustaining glutathione pathways to
detoxify peroxides. The DNA damage caused by chronic oxidative stress
[15], could be ameliorated by the induction of the Kin17 DNA repair gene
[43,44].
Excessive oxidative stress andDNAdamagemakecellsmore prone to
apoptosis. While the importance of the apoptotic pathway in muscle is
still unclear, it has been implicated skeletal muscle denervation and
remodeling, muscular dystrophy, and muscle aging [79–82]. H2O2
promotes apoptosis via activation of the MAP kinase and JNK pathways
and subsequent inactivation of Mcl-1 [83], the muscle isoform of the
Bcl-2 family [84]. Therefore, the up-regulation ofMcl1 indicates that the
Ant1−/− skeletal muscle is attempting to dampen the pro-apoptotic
response. The down-regulation of the pro-apoptotic Bik,Moap1, Chek2,
and Pla2g6 genes would further impede apoptosis. Finally, the down-
regulation of the ornithine decarboxylase-1 gene (Odc1) indicates a
down-regulation of polyamine biogenesis, which could also inhibit
apoptosis by blocking the translocation of BAX into mitochondria [85].
4.2. Transcription factor regulation of the energy deﬁciency in the Ant1−/−
muscle
Having established that the Ant1−/−muscle attempts to compensate
for cytosolicATPdeﬁciency byup-regulatingOXPHOS, and knowing that
PGC-1α is implicated in the regulation of nDNA-encodedmitochondrial
genes, we examined the protein levels of Pgc-1α. Pgc-1α induces
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through the nuclear respiratory factors 1 and 2 (NRF-1 and 2) [66,86]
and Pgc-1α null mice show a reduction in MnSOD and Gpx1 [87].
Furthermore, transgenic mice over-expressing PGC-1α mRNA 16-fold
exhibit a marked increase in exercise capacity and peak oxygen uptake;
an increase in skeletal muscle oxidative metabolism proteins in
including cytochrome c, various OXPHOS complex subunits, fatty acid
oxidation enzymes; a 166% increase in mtDNA and up-regulation of
Tfam transcription factor; and an induction of the antioxidant enzymes
MnSOD, thioredoxin reductase-2, and catalase [75]. Sincewe observed a
marked up-regulation of the Pgc-1α protein in the Ant1−/− skeletal
muscle, we can infer that the up-regulation of mitochondrial OXPHOS
and the increased antioxidant defenses in the Ant1−/− mice are a
consequence of the increased levels of Pgc-1α protein. Up-regulation of
Pgc-1α results in the up-regulation of the mtDNA transcription factor
Tfam, which would increase mtDNA transcript levels. The muscle's
mitochondrial oxidative capacity can also be up-regulated by myogenin
[76]. Similarly, up-regulation of Nrbf1, which interacts with PPARα as
well as other transcription factors known to up-regulate mitochondrial
gene expression, might also be a contributing factor [49].
Inhibition of apoptosis may have been achieved by down-regulation
of c-Myc, which was seen by both the MITOCHIP and protein analyses.
Over-expression of c-Myc has been shown to promote apoptosis in
cultured cells under conditions of serum deprivation and oxidative
stress [88,89], proceeding via release ofmitochondrial cytochrome c and
activation of pro-apoptotic caspases [90]. c-Myc has also been shown to
regulate some Nrf-1 target genes and promote apoptosis by de-
regulating genes involved in mitochondrial function [91]. In a normal
Myc expression background, Nrf-1 over-expression has been shown to
trigger apoptosis in serum-deprived cells [91]. In the skeletal muscle of
Ant1−/−mice Nrf-1 levels andmitochondrial proliferation are increased,
but c-Myc is down-regulated. Therefore, the down-regulation of c-Myc
may be counteracting the pro-apoptotic tendency of increased Nrf-1
levels. The down-regulation of c-Myc might also be important in the
down-regulation of ornithine decarboxylase (Odc1), since Odc1 is a
target gene of c-Myc. The down-regulation of Odc1 should diminish
polyamine synthesis, inhibit the translocation of BAX intomitochondria,
and repress apoptosis [85]. The inhibition of BAX translocation would
also be augmented by the down-regulation of the BAX interacting
Moap1 protein [57,58].
Other c-Myc target genes that are down-regulated include Mtap4
and Hsp86-1. Myc can also regulate the expression of several glycolytic
genes [63] which account for the down-regulation of Ldh1, and EnoI
which are known to be positively regulated by Myc [62,92]. However,
Pfk1 and Gapd should also have been down-regulated but were not
[63]. Overall,Myc down-regulation may have been the mechanism by
which apoptosis was suppressed in the Ant1−/− skeletal muscle in the
presence of high oxygen.
4.3. MITOCHIPmonitoring ofmitochondrial function and for drug screening
OurmouseMITOCHIP isproving tobeapowerful tool foranalyzing the
pathophysiology of mouse models of mitochondrial disease [93]. When
complemented by analysis for key regulatory protein levels, the
MITOCHIP and similar technologies are providingmuch needed readouts
for identifying new mitochondrial therapeutic agents [94,95].
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